Skip to content
Ilaris(canakinumab)
Ilaris (canakinumab) is an antibody pharmaceutical. Canakinumab was first approved as Ilaris on 2009-06-17. It is used to treat cryopyrin-associated periodic syndromes, familial mediterranean fever, juvenile arthritis, and mevalonate kinase deficiency in the USA. It has been approved in Europe to treat cryopyrin-associated periodic syndromes, gouty arthritis, and juvenile arthritis. The pharmaceutical is active against interleukin-1 beta.
Download report
Favorite
COVID-19
Novartis Pharmaceuticals
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
nutritional and metabolic diseasesD009750
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Ilaris
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Canakinumab
Tradename
Proper name
Company
Number
Date
Products
IlariscanakinumabNovartis Pharmaceuticals CorporationN-125319 RX2016-12-22
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
ilarisBiologic Licensing Application2020-09-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cryopyrin-associated periodic syndromes—D056587M04.2
familial mediterranean fever—D010505M04.1
juvenile arthritisEFO_0002609D001171M08
mevalonate kinase deficiency—D054078M04.1
Agency Specific
FDA
EMA
Expiration
Code
canakinumab, Ilaris, Novartis Pharmaceuticals Corporation
2027-06-16Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AC: Interleukin inhibitors
— L04AC08: Canakinumab
HCPCS
Code
Description
J0638
Injection, canakinumab, 1 mg
Clinical
Clinical Trials
102 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.926—1—7
Psoriatic arthritisD015535EFO_0003778L40.5———1—1
SpondylarthritisD025241———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Juvenile arthritisD001171EFO_0002609M08117——8
Gouty arthritisD015210—25——7
Cryopyrin-associated periodic syndromesD056587M04.2——7——7
Non-small-cell lung carcinomaD002289123——6
Type 2 diabetes mellitusD003924EFO_0001360E11—42——5
Adult-onset still's diseaseD016706EFO_0007135M06.1—11——2
Cytokine release syndromeD000080424D89.83——1—12
AtherosclerosisD050197EFO_0003914I25.1—11——2
Lung neoplasmsD008175C34.90—11——2
Pancreatic neoplasmsD010190EFO_0003860C25——1——1
Show 3 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190D4623———4
Schnitzler syndromeD019873EFO_1001165—3———3
Covid-19D000086382U07.1—1——12
Type 1 diabetes mellitusD003922EFO_0001359E10—2———2
MelanomaD008545—1———1
Familial mediterranean feverD010505M04.1—1———1
GoutD006073EFO_0004274M10—1———1
Glucose intoleranceD018149HP_0000833R73.03—1———1
Knee osteoarthritisD020370EFO_0004616M17—1———1
Alzheimer diseaseD000544EFO_0000249F03—1———1
Show 29 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Triple negative breast neoplasmsD0647262————2
Pancreatic ductal carcinomaD0214411————1
Renal cell carcinomaD0022921————1
Macular degenerationD008268EFO_0001365H35.301————1
Healthy volunteers/patients—1————1
FeverD005334HP_0001945R50.91————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCANAKINUMAB
INNcanakinumab
Description
Immunoglobulin G1, anti-[Homo sapiens interleukin 1, beta (IL1B)] human monoclonal ACZ885; gamma1 heavy chain (Homo sapiens VH-IGHG1*03) (221-214’)-disulfide with kappa light chain (Homo sapiens V-KAPPA-IGKC*01); (227-227’’:230-230’’)-bisdisulfide dimer
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)CANAKINUMAB
Structure (InChI/SMILES or Protein Sequence)
>4G5Z:H|canakinumab antibody fragment heavy chain QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPAKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLY LQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVAP >4G5Z:L|canakinumab antibody fragment light chain EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEA EDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG
Identifiers
PDB4G5Z, 4G6J, 5BVJ, 5BVP
CAS-ID914613-48-2
RxCUI853491
ChEMBL IDCHEMBL1201834
ChEBI ID—
PubChem CID—
DrugBankDB06168
UNII ID37CQ2C7X93 (ChemIDplus, GSRS)
Target
Agency Approved
IL1B
IL1B
Organism
Homo sapiens
Gene name
IL1B
Gene synonyms
IL1F2
NCBI Gene ID
3553
Protein name
interleukin-1 beta
Protein synonyms
Catabolin, IL-1 beta, interleukin 1beta, preinterleukin 1 beta, pro-interleukin-1-beta
Uniprot ID
Q9UCT6
Mouse ortholog
Il1b (16176)
interleukin-1 beta (Q2M4J6)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Ilaris - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 7,397 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,849 adverse events reported
View more details